David Kong is a Cardiology physician affiliated with Duke University. OpenAlex indexes 137 publications with 6,657 citations (h-index 37); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2100 Erwin Rd
Dumc Box 3850
Durham, NC 277100001
Telephone
919-620-4467Registry record last updated 5 Jul 2013.
Clinical trials
- Study of Access Site for Enhancing PCI in STEMI for Seniors (SAFE STEMI for Seniors)
Sponsor: David Kong, M.D.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- W. L. Gore & Associates, Inc.Program year20251 payment
- RADIOMETER AMERICA, INCProgram year20251 payment
- Philips North America LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2010–2010 per NIH RePORTER. The latest:
- ACC/Duke Partnership for a National Cardiovascular Research Infrastructure (NCRI)
Duke University
FY2010$1,302,058RC2HL101512
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
European Heart Journal - Cardiovascular Pharmacotherapy
2024 - Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
Journal of the American College of Cardiology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Pamela Douglas, MD
Duke University
Adrian Hernandez, MD
Duke University
Scott Antonia, MD
Duke University
Jonathan Piccini, MD
Duke University
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”